Search results
Showing 46 to 60 of 67 results for lenalidomide
Awaiting development Reference number: GID-TA11815 Expected publication date: TBC
Awaiting development Reference number: GID-TA11830 Expected publication date: TBC
In development Reference number: GID-TA10905 Expected publication date: TBC
Discontinued Reference number: GID-TA10171
Discontinued Reference number: GID-TA10926
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma treatments.These...
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)
Evidence-based recommendations on zanubrutinib (Brukinsa) for marginal zone lymphoma after anti-CD20-based treatment in adults.
Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Discontinued Reference number: GID-TA10133